*DIL2713298* TEST REPORT

Reg.No : DIL2713298 Reg.Date : 16-Dec-2024 /10:44

Name : MR.DR.MUBASHIR Collection : 16-Dec-2024 /10:37
Age\Sex : 34 Years\Male Received : 16-Dec-2024 /11:02
Referred By : LIK/DSNR-39 LIFE CARE DIAGNOSTIC SERVICE Report : 16-Dec-2024 /12:37
(C)
Referral Dr : SELF. Barcode : 000994083600
Clinical Biochemistry
UREA
TEST NAME OBSERVED VALUE UNITS BIOLOGICAL REF. RANGE
BLOOD UREA. 28.3 mg/dL 16-48
Method:Urease (GLDH) /Kinetic

Interpretation :

Elevated levels of urea are observed in pre renal, renal & post renal conditions.

Prerenal conditions ±Diabetes Mellitus, dehydration, cardiac failure, haematemesis, severe burns & high fever etc.

Renal conditions ±Kidney diseases.

Post renal conditions ±Includes enlargement of prostate, stones in urinary tract, tumor of bladder. Urinary tract obstruction, Pyelonephritis.

Decreased values have been reported in severe liver disease, protein malnutrition & pregnancy.

Sample Type : SERUM

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.S.APOORVA
MD BIOCHEMISTRY
Consultant Biochemist

**** END OF REPORT ****

Page 1 of 13
 *DIL2713298* TEST REPORT
Reg.No : DIL2713298 Reg.Date : 16-Dec-2024 /10:44
Name : MR.DR.MUBASHIR Collection : 16-Dec-2024 /10:37
Age\Sex : 34 Years\Male Received : 16-Dec-2024 /11:02
Referred By : LIK/DSNR-39 LIFE CARE DIAGNOSTIC SERVICE Report : 16-Dec-2024 /12:37
(C)
Referral Dr : SELF. Barcode : 000994083600
Clinical Biochemistry
URIC ACID (UA)
TEST NAME OBSERVED VALUE UNITS BIOLOGICAL REF. INTERVAL
URIC ACID 7.1 mg/dL 3.4-7.0
Method:Uricase/End Point

Interpretation :

Elevations of uric acid occur in renal failure, pre-renal azotemia, gout, lead poisoning, excessive cell destruction (e.g., following chemotherapy),
hemolytic anemia, and congestive heart failure and after myocardial infarction. Uric acid is also increased in some endocrine disorders, acidosis,
toxemia of pregnancy, hereditary gout, and glycogen storage disease type.

Sample Type : SERUM

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.S.APOORVA
MD BIOCHEMISTRY
Consultant Biochemist

**** END OF REPORT ****

Page 2 of 13
 *DIL2713298* TEST REPORT
Reg.No : DIL2713298 Reg.Date : 16-Dec-2024 /10:44
Name : MR.DR.MUBASHIR Collection : 16-Dec-2024 /10:37
Age\Sex : 34 Years\Male Received : 16-Dec-2024 /11:02
Referred By : LIK/DSNR-39 LIFE CARE DIAGNOSTIC SERVICE Report : 16-Dec-2024 /12:41
(C)
Referral Dr : SELF. Barcode : 000994083600
HORMONES
VITAMIN - B12
TEST NAME OBSERVED VALUE UNITS BIOLOGICAL REF. RANGE
Vitamin B-12 192.00 pg/mL 197-771
Method:ECLIA

INTERPRETATION :
* Vitamin B-12 is a member of the vitamin B complex. It contains cobalt and is also known as cobalamin.
* B-12 is necessary for the synthesis of RBCs, maintenance of the nervous system and growth and development in childern.
* Increased in Myeloproliferative disorders, leukemias, leucocytosis, liver disorders like hepatitis, cirrhosis, hepatic coma.
* Decreased in individuals with pernicious anemia, individuals with gastrointestinal disorders.vegetarians and older adults.

Sample Type : SERUM

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.S.APOORVA
MD BIOCHEMISTRY
Consultant Biochemist

**** END OF REPORT ****

Page 3 of 13
 *DIL2713298* TEST REPORT
Reg.No : DIL2713298 Reg.Date : 16-Dec-2024 /10:44
Name : MR.DR.MUBASHIR Collection : 16-Dec-2024 /10:37
Age\Sex : 34 Years\Male Received : 16-Dec-2024 /11:02
Referred By : LIK/DSNR-39 LIFE CARE DIAGNOSTIC SERVICE Report : 16-Dec-2024 /12:41
(C)
Referral Dr : SELF. Barcode : 000994083600
HORMONES
VITAMIN D TOTAL 25, OH
TEST NAME OBSERVED VALUE UNITS BIOLOGICAL REF. RANGE
Vitamin D Total 25, OH 23.70 ng/mL Deficiency : < 20
Method:ECLIA Preferred : 30 - 100
Intoxication : > 100

Interpretation:
1. The Assay measures total 25-hydroxyvitamin D, which includes levels of both 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
2. vitamin D is absorbed from exposure to sunlight (Ultra Violet B radiation), from the diet (D2), and from dietary supplements (D2/D3)
3. Vitamin D2 is manufactured through the ultraviolet irradiation of ergosterol from yeast in plants, and vitamin D3 through the
ultraviolet irradiation of 7-dehydrocholesterol from lanolin in the skin.
4. Both D2 and D3 are converted to 25-hydroxyvitamin D (25-OH) in the liver which is used to determine the vitamin D status
5. 25-Hydroxyvitamin D levels equal and below 15-20 ng/ml are inversely associated with parathyroid hormone levels until the
former reach 30 to 40 ng/ml, at which point parathyroid hormone levels begin to level off.
6. Vitamin D is required for the absorption of Calcium and phosphorous in the body. Only 10-15% of calcium is absorbed due to
deficiency.
7. Risk Factors associated with deficiency of vitamin D are inadequate vitamin D intake, insufficient sun exposure, winter season,
older age, female sex, anticonvulsant-drug therapy, dialysis, nephrotic syndrome.
8. Deficiency of Vitamin D with no known risk factors is also seen in patients with coronary artery disease, hypertension, diabetes
mellitus, hypercholesterolemia, substance abuse, and asthma
9. Supplementation of type of Vitamin D2 or D3 is important in the interpretation of 25-hydroxyvitamin D levels, vitamin D2 is
approximately 30% as effective as vitamin D3 in maintaining serum 25-hydroxyvitamin D levels.

Sample Type : SERUM

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.S.APOORVA
MD BIOCHEMISTRY
Consultant Biochemist

**** END OF REPORT ****

Page 4 of 13
 *DIL2713298* TEST REPORT
Reg.No : DIL2713298 Reg.Date : 16-Dec-2024 /10:44
Name : MR.DR.MUBASHIR Collection : 16-Dec-2024 /10:37
Age\Sex : 34 Years\Male Received : 16-Dec-2024 /11:02
Referred By : LIK/DSNR-39 LIFE CARE DIAGNOSTIC SERVICE Report : 16-Dec-2024 /12:37
(C)
Referral Dr : SELF. Barcode : 000994083600
Clinical Biochemistry
CALCIUM
TEST NAME OBSERVED VALUE UNITS BIOLOGICAL REF. RANGE
SERUM CALCIUM 8.05 mg/dL 8.6 - 10.2
Method:BAPTA

Sample Type : SERUM

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.S.APOORVA
MD BIOCHEMISTRY
Consultant Biochemist

**** END OF REPORT ****

Page 5 of 13
 *DIL2713298* TEST REPORT
Reg.No : DIL2713298 Reg.Date : 16-Dec-2024 /10:44
Name : MR.DR.MUBASHIR Collection : 16-Dec-2024 /10:37
Age\Sex : 34 Years\Male Received : 16-Dec-2024 /11:02
Referred By : LIK/DSNR-39 LIFE CARE DIAGNOSTIC SERVICE Report : 16-Dec-2024 /12:37
(C)
Referral Dr : SELF. Barcode : 000994083600
Clinical Biochemistry
CREATININE SERUM
TEST NAME OBSERVED VALUE UNITS BIOLOGICAL REF. RANGE
SERUM CREATININE 0.96 mg/dL 0.70-1.30
Method:Jaffes Kinetic

Sample Type : SERUM

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.S.APOORVA
MD BIOCHEMISTRY
Consultant Biochemist

**** END OF REPORT ****

Page 6 of 13
 *DIL2713298* TEST REPORT
Reg.No : DIL2713298 Reg.Date : 16-Dec-2024 /10:44
Name : MR.DR.MUBASHIR Collection : 16-Dec-2024 /10:37
Age\Sex : 34 Years\Male Received : 16-Dec-2024 /11:02
Referred By : LIK/DSNR-39 LIFE CARE DIAGNOSTIC SERVICE Report : 16-Dec-2024 /12:37
(C)
Referral Dr : SELF. Barcode : 000994083600
Clinical Biochemistry
FASTING BLOOD GLUCOSE (FBS)
TEST NAME OBSERVED VALUE UNITS BIOLOGICAL REF. RANGE
FASTING PLASMA GLUCOSE 73.3 mg/dL 74-99
Method:Hexokinase/GOD-POD

Sample Type : FLOURIDE PLASMA (F)

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.S.APOORVA
MD BIOCHEMISTRY
Consultant Biochemist

**** END OF REPORT ****

Page 7 of 13
*DIL2713298* TEST REPORT
Reg.No : DIL2713298 Reg.Date : 16-Dec-2024 /10:44
Name : MR.DR.MUBASHIR Collection : 16-Dec-2024 /10:37
Age\Sex : 34 Years\Male Received : 16-Dec-2024 /11:08
Referred By : LIK/DSNR-39 LIFE CARE DIAGNOSTIC SERVICE Report : 16-Dec-2024 /11:19
(C)
Referral Dr : SELF. Barcode : 000994083500
Haematology
COMPLETE BLOOD PICTURE(CBP)
TEST NAME OBSERVED VALUE UNITS BIOLOGICAL REF. RANGE
HAEMOGLOBIN 15.7 g/dL 13.0-17.0
Method:Colorimetric,Non cyanide
PCV 47.9 % 40-50
Method:CALCULATED
MCV 86.3 fl 83-101
Method:CALCULATED
MCH 28.3 pg 27-32
Method:CALCULATED
MCHC 32.8 g/dL 31.5-34.5
Method:CALCULATED
RDW 13.8 % 11.6-14.0
Method:CALCULATED
R D W (SD) 43.0 fl 39-46
Method:CALCULATED
TOTAL RBC COUNT 5.55 mil./cmm 4.5-5.5
Method:Electrical Impendance/Microscopy
PLATELET COUNT 2.56 lakhs/cumm 1.5-4.1
Method:Electrical Impendance/Microscopy
TOTAL WBC COUNT 5370 cells/cmm 4000-10000
Method:Electrical Impendance/Microscopy
DIFFERENTIAL COUNT.
NEUTROPHILS. 43.8 % 40-80
Method:SF Cube Cell Analysis Technique / Microscopy.
ABSOLUTE NEUTROPHILIC COUNT 2.35 10^3/mm^3 2.0-7.0
Method:CALCULATED
LYMPHOCYTES 46.3 % 20-40
Method:Flowcytometry & Microcopy (Leishman stain)
ABSOLUTE LYMPHOCYTE COUNT 2.49 10^3/mm^3 1-3
Method:CALCULATED
EOSINOPHILS 2.5 % 1-6
Method:Flowcytometry & Microcopy (Leishman stain)
ABSOLUTE EOSINOPHIL COUNT 0.13 10^3/mm^3 0.02-0.5
Method:CALCULATED
MONOCYTES 7.3 % 2-10
Method:Flowcytometry & Microcopy (Leishman stain)
ABSOLUTE MONOCYTE COUNT 0.39 10^3/mm^3 0.2-1.0
Method:CALCULATED
BASOPHILS 0.1 % 0-2
Method:Flowcytometry & Microcopy (Leishman stain)
ABSOLUTE BASOPHILS COUNT 0.01 10^3/mm^3 0.02-0.1
PERIPHERAL SMEAR(Microscopy)
R B C MORPHOLOGY NORMOCYTIC NORMOCHROMIC
WBC LYMPHOCYTE PREDOMINANCE
PLATELETS ADEQUATE
Sample Type : Page 8 of 13
 *DIL2713298* TEST REPORT
Reg.No : DIL2713298 Reg.Date : 16-Dec-2024 /10:44
Name : MR.DR.MUBASHIR Collection :
Age\Sex : 34 Years\Male Received :
Referred By : LIK/DSNR-39 LIFE CARE DIAGNOSTIC SERVICE Report :
(C)
Referral Dr : SELF. Barcode : 000994083500

Sample Type : WB EDTA

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.KEERTHI PERI
MD PATH
Consultant Pathologist

**** END OF REPORT ****

Page 9 of 13
 *DIL2713298* TEST REPORT
Reg.No : DIL2713298 Reg.Date : 16-Dec-2024 /10:44
Name : MR.DR.MUBASHIR Collection : 16-Dec-2024 /10:37
Age\Sex : 34 Years\Male Received : 16-Dec-2024 /11:02
Referred By : LIK/DSNR-39 LIFE CARE DIAGNOSTIC SERVICE Report : 16-Dec-2024 /12:37
(C)
Referral Dr : SELF. Barcode : 000994083600
Clinical Biochemistry
LIPID PROFILE (LPD)
TEST NAME OBSERVED VALUE UNITS BIOLOGICAL REF. INTERVAL
LIPID PROFILE (LPD)
TOTAL CHOLESTEROL 185.90 mg/dL Desirable : <200
Borderline : 200 - 239
Method:SPECTROPHOTOMETRY
High : >240
H D L CHOLESTEROL 27.7 mg/dL Negative Risk >60
Method:Enzymatic-CHOD-POD High Risk : < 40
L D L CHOLESTEROL 118.6 mg/dL Optimal : <100
Near optimal : 100-129
Method:Friedewald Formula Borderline : 130-159
High : 160-189
Very high : >/=190
V L D L CHOLESTEROL 39.64 mg/dL 6.0-38.0
Method:Friedewald Formula
TRIGLYCERIDES, 198.2 mg /dl Normal: <150
Method:ENZYMATIC/GPO PAP Borderline: 150 -199
High: 200 - 499
Very High: >/= 500
CHOL/HDL RATIO 6.71 - 3.5-5.0
Method:CALCULATED
LDL/ HDL Ratio 4.28 -
Method:CALCULATED

Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week apart are recommended for Total
Cholesterol, Triglycerides, HDL & LDL Cholesterol.

Reference: National Cholesterol Education Program Adult Treatment Plan III (NCEP-ATP 111) report.

Sample Type : SERUM

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.S.APOORVA
MD BIOCHEMISTRY
Consultant Biochemist

**** END OF REPORT ****

Page 10 of 13
 *DIL2713298* TEST REPORT
Reg.No : DIL2713298 Reg.Date : 16-Dec-2024 /10:44
Name : MR.DR.MUBASHIR Collection : 16-Dec-2024 /10:37
Age\Sex : 34 Years\Male Received : 16-Dec-2024 /11:02
Referred By : LIK/DSNR-39 LIFE CARE DIAGNOSTIC SERVICE Report : 16-Dec-2024 /12:37
(C)
Referral Dr : SELF. Barcode : 000994083600
Clinical Biochemistry
LIVER FUNCTION TEST (LFT)
TEST NAME OBSERVED VALUE UNITS BIOLOGICAL REF. RANGE
TOTAL BILIRUBIN 1.06 mg/dL 0.3-1.2
Method:DIAZO METHOD
DIRECT BILIRUBIN 0.30 mg /dl 0-0.2
Method:DIAZO METHOD
INDIRECT BILIRUBIN 0.76 mg /dl 0.2-0.8
Method:CALCULATED
ALKALINE PHOSPHATASE 100.0 U/L 40-129
Method:PNPP-AMP Buffer - Kinetic
SGOT / AST 20.6 U/L 0-41
Method:IFCC
SGPT / ALT 23.1 U/L Upto 40
Method:MOD-IFCC
TOTAL PROTEIN. 7.0 gm/dL 6.6-8.7
Method:Biuret-End Point
ALBUMIN 4.0 gm/dL 3.5-5.2
Method:BCG
GLOBULIN 3.0 gm/dL 2.5-3.5
Method:CALCULATED
A/G RATIO 1.3 Calculated 1-2.1
Method:CALCULATED

Sample Type : SERUM

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.S.APOORVA
MD BIOCHEMISTRY
Consultant Biochemist

**** END OF REPORT ****

Page 11 of 13
 *DIL2713298* TEST REPORT
Reg.No : DIL2713298 Reg.Date : 16-Dec-2024 /10:44
Name : MR.DR.MUBASHIR Collection : 16-Dec-2024 /10:37
Age\Sex : 34 Years\Male Received : 16-Dec-2024 /11:02
Referred By : LIK/DSNR-39 LIFE CARE DIAGNOSTIC SERVICE Report : 16-Dec-2024 /12:18
(C)
Referral Dr : SELF. Barcode : 000994083600
HORMONES
THYROID PROFILE (T3,T4,TSH) (TFT)
TEST NAME OBSERVED VALUE UNITS BIOLOGICAL REF. RANGE
TOTAL TRIIODOTHYRONINE ( T3 ) 1.28 ng/mL 0.80-2.00
Method:ECLIA
TOTAL THYROXINE ( T4 ) 7.29 µg/dL 5.1-14.1
Method:ECLIA
THYROID STIMULATING HORMONE 2.33 µIU/mL 0.27-4.20
(TSH)
Method:ECLIA

Interpretation:
1. The assay uses 4th generation highly sensitive TSH with a sensitivity of 0.005mIU/mL
2. TSH is used primarily to screen for thyroid disorders as follows:
. -Screening for thyroid dysfunction
. -Diagnosis of hyperthyroidism (Decreased TSH)
. -Diagnosis of Hypothyroidism (Elevated TSH)
. -Diagnosis of pituitary and hypothalamic disorders
. -Monitoring Thyroid replacement therapy
TSH in Pregnancy: In the First trimester, maternal thyroxine-binding globulin rises and Free thyroid hormone T4 decreases. TSH levels
decrease due to the thyrotropic effect of hCG. In later trimesters, TSH increases.
Trimester Specific ranges during pregnancy:
Trimester TSH (mIU/L ) or µIU/mL
First 0.1-2.5 *
Second 0.2-3.0
Third 0.2-3.0
Ref: National Academy of Clinical Biochemistry and The American Association of Clinical Endocrinologists.
Limitations:
TSH levels increase with obesity and age, upper levels with the euthyroid state may be seen in some cases.
There is no high-dose hook effect at TSH concentrations up to 1000 µIU/mL

Sample Type : SERUM

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.S.APOORVA
MD BIOCHEMISTRY
Consultant Biochemist

**** END OF REPORT ****

Page 12 of 13
 *DIL2713298* TEST REPORT
Reg.No : DIL2713298 Reg.Date : 16-Dec-2024 /10:44
Name : MR.DR.MUBASHIR Collection : 16-Dec-2024 /10:37
Age\Sex : 34 Years\Male Received : 16-Dec-2024 /11:08
Referred By : LIK/DSNR-39 LIFE CARE DIAGNOSTIC SERVICE Report : 16-Dec-2024 /13:33
(C)
Referral Dr : SELF. Barcode : 000994083500
Clinical Biochemistry
GLYCATED HAEMOGLOBIN (HBA1C)
TEST NAME OBSERVED VALUE UNITS BIOLOGICAL REF. RANGE
GLYCATED HAEMOGLOBIN (HBA1C) 5.3 % Normal : < 5.7
Method:HPLC Diabetes Mellitus : > 6.5
Increased Risk of Diabetes/Pre -
Diabetes : 5.7 - 6.4
AVERAGE BLOOD GLUCOSE 105.41 mg/dL 90 - 120 - Excellent control
Method:Calculation 121 - 150 - Good Control
151 - 180 - Average Control
181 - 210 - Action Suggested
> 211 - Panic Value

Interpretation:
1.HbA1c test is done using HPLC method certified by National Glycohemoglobin Standardization Program(NGSP) and traceable to Diabetes
Control and Complications Trial (DCCI) reference assay
2.HbA1c assay is used in the screening diagnosis and management of diabetes Mellitus
3. It reflects mean glycemia and level of control for the previous 2-3 months Test can be done any time of the day and in non fasted state
4. Measurement of HbA1c is recommended at 3 months intervals if glycemic control is poor or therapy has changed.
5. A good control of glycemia may reflect on HbA1c Levels towards normal in -3-5 week
6.Hba1c assay may be unreliable in case of altered red cell turnover hemolytic anemia and renal failure may decrease the Hba1c value in such
cases Fasting blood glucose or Fructosamine assay are recommended to be used as a measure of glucose control
7. Hemoglobinopathies may lead to an artifactual increase in assay value this can be ruled out by Hemoglobin electrophoresis studies
Splencectomy and polycythemia raises Hba1c levels
8. Pregnancy in the 2nd 3rd-trimester affects Glycemic control Hence Hba1c are not utilized in the diagnosis of gestational diabetes or in the
postnatal period Recommended use of GDM GTT during pregnancy
Related tests:
fasting Blood glucose, Fructosamine, Glucose tolerance test /OGTT /GCT, Postprandial Blood Glucose microalbumin
References:
International expert committee report on the A1c assay in the Diagnosis of diabetes

Sample Type : WB EDTA

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.S.APOORVA
MD BIOCHEMISTRY
Consultant Biochemist

**** END OF REPORT ****

Page 13 of 13